GUTS Key Statistics, Chart & Performance
The current stock price of GUTS is 1.98 USD. In the past month the price increased by 75.22%. In the past year, price decreased by -14.29%.
GUTS Latest News, Press Relases and Analysis
GUTS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.13 | 218.05B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.04 | 201.58B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.13 | 144.86B | ||
| SYK | STRYKER CORP | 27.67 | 139.33B | ||
| IDXX | IDEXX LABORATORIES INC | 56.9 | 57.29B | ||
| BDX | BECTON DICKINSON AND CO | 13.44 | 55.54B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.38 | 49.78B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.98 | 37.59B | ||
| RMD | RESMED INC | 25.41 | 36.71B | ||
| DXCM | DEXCOM INC | 35.08 | 25.45B | ||
| PODD | INSULET CORP | 69.13 | 22.22B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.52 | 18.46B |
Related stock screener links
About GUTS
Company Profile
Fractyl Health, Inc. is a metabolic therapeutics company. The company is headquartered in Burlington, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2024-02-02. The firm is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
Company Info
FRACTYL HEALTH INC
3 Van De Graaff Drive, Suite 200
Burlington MASSACHUSETTS US
Employees: 103
Phone: 17819028800
FRACTYL HEALTH INC / GUTS FAQ
What does GUTS do?
Fractyl Health, Inc. is a metabolic therapeutics company. The company is headquartered in Burlington, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2024-02-02. The firm is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
Can you provide the latest stock price for FRACTYL HEALTH INC?
The current stock price of GUTS is 1.98 USD. The price increased by 3.13% in the last trading session.
Does FRACTYL HEALTH INC pay dividends?
GUTS does not pay a dividend.
What is the ChartMill rating of FRACTYL HEALTH INC stock?
GUTS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is GUTS stock listed?
GUTS stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of FRACTYL HEALTH INC (GUTS)?
FRACTYL HEALTH INC (GUTS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.29).
Is FRACTYL HEALTH INC (GUTS) expected to grow?
The Revenue of FRACTYL HEALTH INC (GUTS) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
GUTS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to GUTS. When comparing the yearly performance of all stocks, GUTS is one of the better performing stocks in the market, outperforming 93.32% of all stocks.
GUTS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GUTS. GUTS has a bad profitability rating. Also its financial health evaluation is rather negative.
GUTS Financial Highlights
Over the last trailing twelve months GUTS reported a non-GAAP Earnings per Share(EPS) of -2.29. The EPS decreased by -59.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -106.94% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GUTS Forecast & Estimates
11 analysts have analysed GUTS and the average price target is 7.18 USD. This implies a price increase of 262.67% is expected in the next year compared to the current price of 1.98.
For the next year, analysts expect an EPS growth of 0.8% and a revenue growth -100% for GUTS